Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tejashri Purohit-Sheth"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 387-397 (2020)
In the past three decades the field of gene therapy has made remarkable progress, surging from mere laboratory experiments to US Food and Drug Administration (FDA)-approved products that bring significant reduction in disease burden to patients who p
Externí odkaz:
https://doaj.org/article/cd1c44d58c114914aa6ef0bb2ae9c924
Autor:
Najat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, Cong Wang, Tianjiao Dai, Zhenzhen Xu, Xiaofei Wang, Marc Theoret, Tejashri Purohit-Sheth, Bindu George
Publikováno v:
Oncologist
In March 2021, the U.S. Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c679d101df2c4e8b231ab8728b3e3d
https://doi.org/10.1093/oncolo/oyac054
https://doi.org/10.1093/oncolo/oyac054
Autor:
Najat Bouchkouj, Xue Lin, Xiaofei Wang, Donna Przepiorka, Zhenzhen Xu, Tejashri Purohit-Sheth, Marc Theoret
Publikováno v:
Oncologist
In October 2021, the FDA approved brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9232ed36dce588d8590c73dc37bfa1e
https://europepmc.org/articles/PMC9526496/
https://europepmc.org/articles/PMC9526496/
Publikováno v:
Translational Science of Rare Diseases
The field of regenerative medicine is growing rapidly with the introduction of new therapies that have the potential to treat and cure serious medical conditions, including rare diseases, for which there are no available treatments. In the United Sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91340fbadbd882c654df3778339ca27b
http://europepmc.org/articles/PMC6311534
http://europepmc.org/articles/PMC6311534
Autor:
Leslie Ball, Paul Okwesili, John R. Marler, Tejashri Purohit-Sheth, Gary Gensler, Zorayr Manukyan, Ann Meeker-O’Connell, Anne S. Lindblad
Publikováno v:
Clinical trials (London, England). 11(2)
Background Site monitoring and source document verification account for 15%‒30% of clinical trial costs. An alternative is to streamline site monitoring to focus on correcting trial-specific risks identified by central data monitoring. This risk-ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8514380221c7007b41ed823d26d9066f
https://pubmed.ncbi.nlm.nih.gov/24296321
https://pubmed.ncbi.nlm.nih.gov/24296321